Detalles de la búsqueda
1.
Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.
J Infect Dis
; 226(1): 119-127, 2022 08 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34653245
2.
Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate: a randomised, double-blind, placebo-controlled, phase 2a trial.
Lancet Infect Dis
; 23(12): 1360-1369, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37517422
3.
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model.
Front Immunol
; 14: 1188605, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37409116
4.
Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.
Front Immunol
; 13: 852904, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35464450
5.
OVX836 Heptameric Nucleoprotein Vaccine Generates Lung Tissue-Resident Memory CD8+ T-Cells for Cross-Protection Against Influenza.
Front Immunol
; 12: 678483, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34177921
6.
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.
NPJ Vaccines
; 4: 4, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30701093
7.
A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
Vaccine
; 34(11): 1412-21, 2016 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26854906
Resultados
1 -
7
de 7
1
Próxima >
>>